
Opinion|Videos|January 9, 2025
KEYONTE-522: Exploratory Biomarker Analysis in Periop Pembro vs. Placebo + Chemo
Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its implications for treatment strategies.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer
2
Oncologists Weigh BTK/BCL2 Inhibitor Combinations in CLL
3
FDA OKs Guardant360 CDx for Encorafenib Combo in BRAF V600E+ Metastatic CRC
4
Later-Line and Combination Therapies in cGVHD and Future Directions
5





















